AstraZeneca, alongside Pfizer, has secured exemptions from potential U.S. drug tariffs under the Trump administration, a move expected to boost pharmaceutical stocks with minimal downside risk for the companies involved.

In a separate development, AstraZeneca announced the opening of an expanded manufacturing facility in Texas, which will double production capacity for its potassium binder drug Lokelma, used to treat hyperkalemia (high potassium levels in the blood).

Shares of AstraZeneca closed at 12,738.00 pence, up 14.00 pence, or 0.11%, in the latest trading session, reflecting steady investor confidence amid continued operational expansion and favorable policy developments.